2-Bromo-6-nitrophenol ker 1 The drug was developed by

The drug was developed by Valeant Pharmaceuticals and GlaxoSmithKline

4R)-3-acetyloxy-1-[[(2S)-1-[(2-methoxy-2-oxoethyl)-methylamino]-1-oxobutan-2-yl]amino]-4-methyl-1-oxooct-6-en-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]-methylamino]-4-methyl-1-oxopentan-2-yl]-methylamino]-4-methyl-1-oxopentan-2-yl]-methylamino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylamino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]-methylazanium

14bR)-3-(acetyloxy)-4

Purpurin 18 methyl ester has photodynamic activity to induce cancer cell death

Resveratrol induces phase II drug-metabolizing enzymes (anti-initiation activity)

2-Bromo-6-nitrophenol ker 1 The drug was developed by2 Bromo 6 nitrophenol is converted via 2 bromo 6 aminophenol to N acetyl 2 bromo 6 aminophenol. Product information CAS Number: 13073 25 1 Molecular Weight: 218. 00 Formula: C6H4BrNO3 Chemical Name: 2 bromo 6 nitrophenol Smiles: [O ][N+](=O)C1=CC=CC(Br)=C1O InChiKey: VEJSIOPQKQXJAT UHFFFAOYSA N InChi: InChI=1S C6H4BrNO3 c7 4 2 1 3 5(6(4)9)8(10)11 h1 3,9H Technical Data Appearance: Solid Power Purity: 98% (or refer to the Certificate of Analysis)